Home
    • Plans Blog Contact
    Merck & Company Inc logo

    Merck & Company Inc

    MRK
    Last price US$131.41
    Market cap US$305.9b
    12M price change 56.14%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Eli Lilly and CompanyLLY Industry peer Amgen IncAMGN Industry peer Johnson & JohnsonJNJ Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Merck & Company Inc Overview

    Industry: Drug Manufacturers General

    Sector: Healthcare

    Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Merck & Company Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 30, 2026

    Quarterly result summary

    Stored reported-result values did not pass automated reconciliation.

    What changed

    • Open the SEC source filing while these values are reprocessed.

    Source review

    Mavefund has withheld unreconciled figures from the public page.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 1Q26 FORM 10-Q May 04, 2026 Earnings release EXHIBIT 99.1 Apr 30, 2026 SEC filing 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 Feb 24, 2026 Earnings release EXHIBIT 99.1 Feb 03, 2026 Earnings release EXHIBIT 99.2 Feb 03, 2026 SEC filing 3Q25 FORM 10-Q Nov 05, 2025 Earnings release EXHIBIT 99.1 Oct 30, 2025 Earnings release EXHIBIT 99.2 Oct 30, 2025 SEC filing 2Q25 FORM 10-Q (6.30.25) Aug 05, 2025 Earnings release EXHIBIT 99.2 Jul 29, 2025 Earnings release EXHIBIT 99.1 Jul 29, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Merck & Company Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers General industry , Eli Lilly and Company , Amgen Inc , Johnson & Johnson are companies with high ratings.

    Return on Equity

    Score 2.65/5
    Merck & Company Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Merck & Comp... MRK US$305.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.92/5
    Merck & Company Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Merck & Comp... MRK US$305.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers General industry , Eli Lilly and Company , Amgen Inc , Johnson & Johnson are companies with high ratings.

    Leverage

    Score 1.57/5
    Merck & Company Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Merck & Comp... MRK US$305.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Merck & Company Inc logo

    Merck & Company Inc

    US$131.41

    US$45.68

    -65.2% vs price

    US$305.9b

    3.11%

    56.14%